LifeStance Health Group (LFST)
(Delayed Data from NSDQ)
$5.55 USD
+0.04 (0.73%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $5.54 -0.01 (-0.18%) 7:58 PM ET
1-Strong Buy of 5 1
D Value F Growth D Momentum F VGM
LifeStance Health Group (LFST) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$8.64 | $10.00 | $7.00 | 56.81% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for LifeStance Health Group comes to $8.64. The forecasts range from a low of $7.00 to a high of $10.00. The average price target represents an increase of 56.81% from the last closing price of $5.51.
Analyst Price Targets (7 )
Broker Rating
LifeStance Health Group currently has an average brokerage recommendation (ABR) of 2.56 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 2.56 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, two are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 25% and 12.5% of all recommendations. A month ago, Strong Buy made up 25%, while Buy represented 12.5%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 4 | 4 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 2.56 | 2.56 | 2.56 | 2.56 | 2.56 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/6/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/4/2024 | Goldman Sachs | Jamie Perse | Hold | Hold |
2/29/2024 | Not Identified | Not Identified | Strong Sell | Strong Sell |
2/8/2024 | UBS | Kevin Caliendo | Hold | Hold |
11/8/2023 | William Blair | Ryan S Daniels | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.56 |
ABR (Last week) | 2.56 |
# of Recs in ABR | 8 |
Average Target Price | $8.64 |
LT Growth Rate | NA |
Industry | Medical - Outpatient and Home Healthcare |
Industry Rank by ABR | 69 of 253 |
Current Quarter EPS Est: | -0.07 |